A sudden worldwide increase in an antibiotic-resistant bacterium is cause for concern, according to a review in f1000 Medicine Reports.
Faculty of 1000 member Dr. Johann Pitout, of the Department of Pathology and Laboratory Medicine, University of Calgary, urges the medical community to monitor the spread of a multi-drug resistant bacterium before it becomes necessary to use more powerful antibiotics as a first response.
Extended-spectrum β-lactamases (ESBLs) are bacterially-produced enzymes that confer resistance to penicillin-type antibiotics. ESBLs have been commonly linked to nosocomial infections, which are generally treated with intravenously-administered antibiotics such as the carbapenems.
However, in recent years there has been a drastic increase in community-acquired infections, caused by a single strain of ESBL-producing E. coli. Pitout suggests that the rapid spread of this particular strain is due, at least in part, to international travel through high-risk areas such as the Indian subcontinent.
Using carbapenems as the first response to such infections increases the risk of inducing resistance to them in the community, nullifying some of our most powerful antibacterial strategies. Pitout recommends that the medical community should use existing methods to identify infections caused by ESBL-producing bacteria, and empirically test the efficacy of other antibiotics in treating community-acquired infections.
Pitout concludes, "If this emerging public health threat is ignored ... the medical community may be forced to use the carbapenems as the first choice for the empirical treatment of serious [community-acquired UTIs]."